Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways

[1]  C. Podrini,et al.  Metabolism and mitochondria in polycystic kidney disease research and therapy , 2018, Nature Reviews Nephrology.

[2]  Ying Sun,et al.  Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  R. Deberardinis,et al.  Lkb1 deficiency confers glutamine dependency in polycystic kidney disease , 2018, Nature Communications.

[4]  Yi Liu,et al.  A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed , 2018, Scientific Reports.

[5]  M. Eilers,et al.  MYC and tumor metabolism: chicken and egg , 2017, The EMBO journal.

[6]  M. Kilberg,et al.  Asparagine synthetase: Function, structure, and role in disease , 2017, The Journal of Biological Chemistry.

[7]  N. Yuldasheva,et al.  Role of glutamine and interlinked asparagine metabolism in vessel formation , 2017, The EMBO journal.

[8]  P. Igarashi,et al.  microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism , 2017, Nature Communications.

[9]  S. Somlo,et al.  The polycystins are modulated by cellular oxygen-sensing pathways and regulate mitochondrial function , 2017, Molecular biology of the cell.

[10]  A. Boletta,et al.  2-Deoxy-d-Glucose Ameliorates PKD Progression. , 2016, Journal of the American Society of Nephrology : JASN.

[11]  D. di Bernardo,et al.  In Silico Modeling of Liver Metabolism in a Human Disease Reveals a Key Enzyme for Histidine and Histamine Homeostasis , 2016, Cell reports.

[12]  V. Torres,et al.  Food Restriction Ameliorates the Development of Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[13]  G. Germino,et al.  Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease , 2016, EBioMedicine.

[14]  M. Riwanto,et al.  Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease , 2016, PloS one.

[15]  R. Weiss,et al.  The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. , 2015, American journal of physiology. Renal physiology.

[16]  T. Benzing,et al.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease , 2015, Nature Reviews Nephrology.

[17]  P. Harris,et al.  A polycystin-centric view of cyst formation and disease: the polycystins revisited , 2015, Kidney international.

[18]  Kumar Sharma,et al.  Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development , 2014, Nature Medicine.

[19]  Coral Barbas,et al.  Method validation strategies involved in non-targeted metabolomics. , 2014, Journal of chromatography. A.

[20]  V. Torres,et al.  Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. , 2014, The Journal of clinical investigation.

[21]  A. Boletta,et al.  Polycystin-1 Binds Par3/aPKC and Controls Convergent Extension During Renal Tubular Morphogenesis , 2013, Nature Communications.

[22]  E. Henske,et al.  Metabolic reprogramming in polycystic kidney disease , 2013, Nature Medicine.

[23]  A. Boletta,et al.  Defective Glucose Metabolism in Polycystic Kidney Disease Identifies A Novel Therapeutic Paradigm , 2013, Nature Medicine.

[24]  G. Germino,et al.  Network Analysis of a Pkd1-Mouse Model of Autosomal Dominant Polycystic Kidney Disease Identifies HNF4α as a Disease Modifier , 2012, PLoS genetics.

[25]  Kai Simons,et al.  Membrane lipidome of an epithelial cell line , 2011, Proceedings of the National Academy of Sciences.

[26]  Anne M. Evans,et al.  Organization of GC/MS and LC/MS metabolomics data into chemical libraries , 2010, J. Cheminformatics.

[27]  Laurie A. Smith,et al.  Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models , 2010, Nature Medicine.

[28]  O. Fiehn,et al.  A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. , 2010, American journal of physiology. Renal physiology.

[29]  C. Wodarczyk,et al.  A Novel Mouse Model Reveals that Polycystin-1 Deficiency in Ependyma and Choroid Plexus Results in Dysfunctional Cilia and Hydrocephalus , 2009, PloS one.

[30]  Ning He,et al.  Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. , 2009, Human molecular genetics.

[31]  P. Pandolfi,et al.  Polycystin-1 Regulates Extracellular Signal-Regulated Kinase-Dependent Phosphorylation of Tuberin To Control Cell Size through mTOR and Its Downstream Effectors S6K and 4EBP1 , 2009, Molecular and Cellular Biology.

[32]  B. Magenheimer,et al.  A tumor necrosis factor-α–mediated pathway promoting autosomal dominant polycystic kidney disease , 2008, Nature Medicine.

[33]  G. Germino,et al.  Essential role of cleavage of Polycystin-1 at G protein-coupled receptor proteolytic site for kidney tubular structure , 2007, Proceedings of the National Academy of Sciences.

[34]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[35]  O. Ibraghimov-Beskrovnaya,et al.  Mechanical stimuli induce cleavage and nuclear translocation of the polycystin-1 C terminus. , 2004, The Journal of clinical investigation.

[36]  G. Germino,et al.  Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Igarashi,et al.  Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. , 2002, Journal of the American Society of Nephrology : JASN.

[38]  Christine Brun,et al.  In silico prediction of protein-protein interactions in human macrophages , 2001, BMC Research Notes.

[39]  G. Germino,et al.  The Molecular Basis of Focal Cyst Formation in Human Autosomal Dominant Polycystic Kidney Disease Type I , 1996, Cell.

[40]  Yves Pirson,et al.  Autosomal dominant polycystic kidney disease , 1992, The Lancet.

[41]  V. Patel,et al.  PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice. , 2018, American journal of physiology. Renal physiology.

[42]  E. Gottlieb,et al.  Analysis of Cell Metabolism Using LC-MS and Isotope Tracers. , 2015, Methods in enzymology.

[43]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..